Chinese drug regulators completed an expert panel review of a COVID-19 mRNA vaccine co-developed by Fosun Pharma and Germany's BioNTech, and now the shot is in the administrative review stage, according to Fosun.
Chinese authorities plan to use the vaccine, which goes by the brand name Comirnaty, as a booster shot for people who have received inactivated-virus vaccines, people close to regulators told Caixin. The booster shot is likely to be offered free of charge.